DA
AXSM icon

Duality Advisers’s Axsome Therapeutics AXSM Stock Holding History

Duality Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-36,793
Closed -$1.21M – 499
2021
Q3 		$1.21M Buy
+36,793
New +$1.43M 0.09% 318
2021
Q2 		– Sell
-16,794
Closed -$951K – 534
2021
Q1 		$951K Buy
16,794
+10,289
+158% +$724K 0.08% 356
2020
Q4 		$530K Sell
6,505
-9,695
-60% -$725K 0.04% 437
2020
Q3 		$1.15M Buy
+16,200
New +$1.26M 0.07% 341

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Duality Advisers's AXSM Position: Q4 2021 in Review

Duality Advisers sold out of Axsome Therapeutics (AXSM) in Q4 2021, closing a stake of 36,793 shares — an estimated $1.21M sold.

Duality Advisers first reported a position in AXSM in Q3 2020 and held it in 4 quarters. The position peaked at $1.21M in Q3 2021. 167 funds tracked by Wall St. Rank hold AXSM as of Q4 2021.

  • Duality Advisers reported no remaining Axsome Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Duality Advisers sold 36,793 Axsome Therapeutics shares in Q4 2021, an estimated $1.21M.
  • Duality Advisers first reported a position in Axsome Therapeutics in Q3 2020 and held it in 4 quarters.
  • Duality Advisers's Axsome Therapeutics position peaked at $1.21M in Q3 2021.
  • 167 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2021.

Based on Duality Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.